Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 871-874, 2007.
Article
Dans Chinois
| WPRIM
| ID: wpr-298490
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate tolerance and toxicity of high-dose epirubicin regimen CEF-100 as adjuvant therapy for breast cancer.</p><p><b>METHODS</b>From March 2005 to October 2006, 98 patients with stage I - III a breast cancer were randomly assigned to receive postoperative chemotherapy with CEF-100 regimen (epirubicin 100 mg/m2, dl per 21 days for 6 cycles, n =48) or CEF-60 regimen (epirubicin 60 mg/m2, dl per 21 days for 6 cycles, n = 50). Blood routine test were done every cycle, liver and kindey function were examined and adverse effects were recorded after every cycle.</p><p><b>RESULTS</b>No difference of average leucocyte or neutrophil count (P >0.05) was observed in every cycle. Adverse effects of digestive tract and damage of liver function in CEF-100 group were more severe than that in CEF-60 group (P <0.05), but all adverse effects could be relieved by treatment. No severe non-hematological toxicity and cardiac toxicity in both groups were observed (P <0.05). There was no death caused by chemotherapy.</p><p><b>CONCLUSION</b>Our data shows that high dose epirubicin-containing CEF regimen is safe and tolerable for postoperative chemotherapy of breast cancer patient, and the adverse effects could be relieved by marrow support and liver-protection therapy. Further observation and longer follow-up is still needed in order to evaluate the efficacy of this high dose regimen.</p>
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Aspartate aminotransferases
/
Chirurgie générale
/
Vomissement
/
Sang
/
Tumeurs du sein
/
Épirubicine
/
Protocoles de polychimiothérapie antinéoplasique
/
Études de suivi
/
Traitement médicamenteux adjuvant
/
Carcinome lobulaire
Type d'étude:
Étude observationnelle
/
Étude pronostique
Limites du sujet:
Adulte
/
Femelle
/
Humains
langue:
Chinois
Texte intégral:
Chinese Journal of Oncology
Année:
2007
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS